Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05494164
Other study ID # 2022-03
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date August 7, 2022
Est. completion date May 23, 2023

Study information

Verified date April 2024
Source Cairo University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

the study is intended to test the effect of Nigella sativa nasal oil drops on selected outcomes among patients with chronic rhinosinusitis using prospective clinical trial design. To achieve the aim of the current trial the following research hypotheses are postulated: H1. The total severity of symptoms mean scores of patients with CRS who will use Nigella sativa nasal oil drops will be different from the total severity of symptoms mean scores of a control group. H2. The total sleep quality mean scores of patients with CRS who will use Nigella sativa nasal oil drops will be different from the total sleep quality mean scores of a control group. H3. The total patient satisfaction mean scores of patients with CRS who will use Nigella sativa nasal oil drops will be different from the total patient satisfaction mean scores of a control group.


Description:

The clinical trial will be conducted to examine the effect of administering a daily dose of 100 mg Nigella sativa nasal oil drops for four weeks on selected outcomes which include severity of symptoms, sleep quality and patient satisfaction among patients with chronic rhinosinusitis. The trial will be conducted on 102 adult patients with chronic rhinosinusitis who will be randomly assigned to either a study group (51 participant) who will receive Nigella sativa beside the standard treatment or a control group (51 participant) who will receive the standard treatment only. The current trial will be conducted in the Ear, Nose and Throat (ENT) outpatient clinic at Kasr Al Ainy University Hospital, Cairo, Egypt. Required data will be collected by using the following four tools: (a) Demographic and Medical Data Form (DMDF), (b) Sino-Nasal Outcome Test 22 (SNOT-22), (c) Sleep Quality Scale (SQS) and (d) Treatment Satisfaction Questionnaire for Medication (TSQM). The researcher prepared a flyer that will be handed in for the study group to explain how the oil will be utilized by the participants. The formal initial approval was obtained from Research Ethics Committee at Faculty of Nursing, Cairo University and an official permission was also obtained from the hospital administrators for conducting the trial. The researcher collaborated with Emeritus Professor in Pharmacognosy from the College of Pharmacy for the preparation of N. sativa nasal oil drops from Nigella sativa and Sesame seeds. Thereafter, data collection will be carried out from both groups using the following five steps as follows: recruitment and randomization; interviewing; initial assessment; intervention; follow-up and monitoring.


Recruitment information / eligibility

Status Completed
Enrollment 102
Est. completion date May 23, 2023
Est. primary completion date May 23, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years to 60 Years
Eligibility Inclusion Criteria: - Adult patients from 18 to 60 years old, - able to communicate, - having a confirmed diagnosis of CRS by signs and symptoms and meeting the criteria of having twelve consecutive weeks or longer of two or more of the following signs and symptoms will be recruited for the current trial: (a) mucopurulent drainage, (b) nasal obstruction/congestion, (c) facial pain-pressure-fullness and (d) decreased sense of smell; and one or more of the following signs and symptoms: (a) purulent mucus or edema in middle meatus or anterior ethmoid region or (b) radiographic imaging showing sinus inflammation. Exclusion Criteria: - Pregnancy, - lactating mothers, - immunodeficiency, - scheduled for surgical management for nasal polyposis, - fever more than 37.8 ?C, - patients with coagulation disorders or using anticoagulants, - patients taking non-potassium sparing diuretics, - patients allergic to N. sativa (patients reactive to sensitivity test) - patients using any type of natural products as a complementary therapy at the time of the trial.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Nigella sativa nasal oil drops
in addition to the standard treatment, the study group will receive one nasal drop of the prepared N. sativa nasal oil drops in each nostril twice daily which are equivalent to a daily dose of 100 milligram of a pure N. sativa oil for four weeks. N. sativa oil was prepared from N. sativa seeds and it was mixed in Sesame oil with a ratio of 1 to 1. The prepared drops will then be placed in dark containers with a specific dropper. Each participant will be instructed regarding the dose, proper position and steps, assisted by a flyer which will be developed by the researcher.
Drug:
standard treatment
intranasal corticosteroids in addition to nasal irrigation with sea water; for patients with allergy the standard treatment is oral antihistamines with or without oral corticosteroids.

Locations

Country Name City State
Egypt Cairo University Cairo

Sponsors (1)

Lead Sponsor Collaborator
Cairo University

Country where clinical trial is conducted

Egypt, 

Outcome

Type Measure Description Time frame Safety issue
Primary Severity of physiological symptoms as measured by Sino-Nasal Outcome Test 22 (SNOT-22) SNOT-22 consists of 22 items that measure four domains as follows: (a) nasal symptoms domain that contains eight items, (b) otologic symptoms domain which includes four items, (c) sleep symptoms domain which includes seven items and (d) emotional symptoms domain that contains three items. SNOT-22 is scored using a Likert scale where 0="No problem", 1="Very mild problem", 2="Mild or slight problem", 3="Moderate problem", 4="Severe problem" and 5="Problem as bad as it can be". The overall scores of the SNOT-22 is ranged from 0 to 110 with higher scores suggesting symptom severity. from two to four weeks
Primary Sleep quality as measured by Sleep Quality Scale (SQS) Sleep Quality Scale (SQS) consists of 28 items, which evaluate six domains of sleep quality as follows: (a) daytime dysfunction/symptoms which contain twelve items, (b) restoration after sleep which include four items, (c) difficulty falling asleep that contain four items, (d) difficulty getting up that include three items, (e) difficulty in maintaining asleep which contain two items and (f) satisfaction with sleep which include three items. Sleep Quality Scale is scored through a four-point, Likert-type scale; (0 = "few," 1 = "sometimes," 2 = "often," and 3 = "almost always"). Scores on items belong to factors 2 and 5 (restoration after sleep and satisfaction with sleep) are reversely scored. Total scores are ranged from 0 to 84, with higher scores denoting more acute sleep problems. from two to four weeks
Secondary severity of sleep and emotional symptoms as measured by Sino-Nasal Outcome Test 22 (SNOT-22) (sleep and emotional symptoms domains) SNOT-22 consists of 22 items that measure four domains as follows: (a) nasal symptoms domain that contains eight items, (b) otologic symptoms domain which includes four items, (c) sleep symptoms domain which includes seven items and (d) emotional symptoms domain that contains three items. SNOT-22 is scored using a Likert scale where 0="No problem", 1="Very mild problem", 2="Mild or slight problem", 3="Moderate problem", 4="Severe problem" and 5="Problem as bad as it can be". The overall scores of the SNOT-22 is ranged from 0 to 110 with higher scores suggesting symptom severity. from two to eight weeks
Secondary patient satisfaction as measured by Treatment Satisfaction Questionnaire with Medications (TSQM) Treatment Satisfaction Questionnaire for Medication includes 14 items that assess four key dimensions of treatment satisfaction: (a) effectiveness which includes three items, (b) side Effects which contain five items, (c) convenience that include three items and (d) global Satisfaction that contain three items. Item of TAQM are scaled on 5 or 7 point Likert scale, except one item which is answered with 1= "Yes" or 0= "No". Scores for each domain are calculated independently by adding the TSQM items in each domain and then transforming the composite score into a value ranging from 0 to 100; higher values indicate higher satisfaction, better perceived effectiveness, lower burden associated to side-effects, better convenience. from two to eight weeks
See also
  Status Clinical Trial Phase
Completed NCT04131686 - NAC Inhalation in the Treatment Of Symptomatic acuTe rhinosinUSitis
Completed NCT02692794 - Large Scale Cerebral Oximetry During Sinus Endoscopy N/A
Completed NCT01988779 - Oral Versus Topical Antibiotics for Chronic Rhinosinusitis Exacerbations Phase 3
Completed NCT01254916 - The Sinonasal Outcome Test - 22, Validated for Danish Patients N/A
Completed NCT03614923 - Etokimab in Adults With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) Phase 2
Completed NCT03781804 - Study Evaluating the Efficacy and Safety of Intranasal Administration of OPN-375 in Subjects With Chronic Rhinosinusitis With or Without the Presence of Nasal Polyps Phase 3
Completed NCT01198912 - Influence of Oral Doxycycline on Wound Healing After Endonasal Endoscopic Sinus Surgery for Chronic Rhinosinusitis With and Without Nasal Polyposis: a Double-blind Randomized Placebo-controlled Trial Phase 2
Active, not recruiting NCT06457100 - Esmolol Versus Lidocaine on the Quality of Postoperative Recovery in Patients Undergoing Functional Endoscopic Sinus Surgery Phase 1/Phase 2
Completed NCT03280537 - A Clinical Trial of Omalizumab in Participants With Chronic Rhinosinusitus With Nasal Polyps Phase 3
Terminated NCT02285283 - Itraconazole for Fungal Sensitive Chronic Rhinosinusitis With Nasal Polyps Phase 2/Phase 3
Completed NCT02307825 - Azithromycin for Patients With Chronic Rhinosinusitis Failing Medical and Surgical Therapy Phase 4
Completed NCT02218307 - The Use of Antibiotic Sinonasal Rinse After Sinus Surgery Phase 4
Recruiting NCT01024075 - Effect of Sinufoam-Dexamethasone Mixture on Post Endoscopic Sinus Surgery Outcomes Phase 4
Completed NCT01002313 - Effect of Prednisone onTregs and TH17 Phase 1
Completed NCT00396162 - Use of Probiotics as Adjunctive Treatment for Chronic Rhinosinusitis Phase 4
Completed NCT03280550 - A Clinical Trial of Omalizumab in Participants With Chronic Rhinosinusitis With Nasal Polyps Phase 3
Recruiting NCT05935683 - Rhinosinusitis Italian Network: the Italian Registry for Severe, Uncontrolled Chronic Rhinosinusitis
Completed NCT03478930 - An Extension Study of Omalizumab in Participants With Chronic Rhinosinusitis With Nasal Polyps Phase 3
Completed NCT01943370 - Early Saline Irrigation to Decrease Post-operative Endoscopic Debridement N/A
Completed NCT02154555 - A Randomized Controlled Trial Evaluating Postoperative Debridement Following Endoscopic Sinus Surgery N/A